BioGaia AB (publ) (FRA:BGLA)

Market Cap	948.49M
Revenue (ttm)	130.81M
Net Income (ttm)	28.55M
Shares Out	n/a
EPS (ttm)	0.28
PE Ratio	33.22
Forward PE	n/a
Dividend	0.63 (6.85%)
Ex-Dividend Date	May 8, 2025

Volume	n/a
Average Volume	32
Open	9.34
Previous Close	9.26
Day's Range	9.34 - 9.34
52-Week Range	8.36 - 12.00
Beta	n/a
RSI	48.11
Earnings Date	Jul 18, 2025

About BioGaia AB

BioGaia AB (publ), a healthcare company, provides probiotic products worldwide. The company operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. The Adult Health segment provides gut health tablets, bone health tablets and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee’s dairy product. The Other segment provides packagin...

• Industry: Pharmaceutical Preparations
• Founded: 1990
• Employees: 225
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BGLA

Financial Performance

In 2024, BioGaia AB's revenue was 1.42 billion, an increase of 9.73% compared to the previous year's 1.30 billion. Earnings were 351.39 million, a decrease of -3.82%.

Financial numbers in SEK